Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 26, showing 5 Applications out of 126 total, starting on record 21, ending on 25

# Protocol No Study Title Investigator(s) & Site(s)

21.

ECCT/21/05/06   VAC52150EBL2010 ;Phase 2
    An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen   
Principal Investigator(s)
1. Prof. Omu Anzala Omu Anzala
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View

22.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View

23.

ECCT/21/11/05   SOLIDARITY TRIAL PLUS
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. loice Ombajo
Site(s) in Kenya
1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county)
2. The Nairobi Hospital (Nairobi City county)
 
View

24.

ECCT/20/04/01   Solidarity
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kilifi Kemri-Wellcome (Kilifi county)
2. Kenya National Hospital (Nairobi City county)
3. Coast PGH (Mombasa county)
4. The Nairobi Hospital (Nairobi City county)
5. Aga Khan University Hospital (Nairobi City county)
6. Moi Teahing and Referal Hospital (Uasin Gishu county)
7. Kenyatta University teaching research and referal hospital (Kiambu county)
 
View

25.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
View